Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Long-Term Investments (2024 - 2025)

Stoke Therapeutics (STOK) has 2 years of Long-Term Investments data on record, last reported at $80.3 million in Q3 2025.

  • For Q3 2025, Long-Term Investments rose 168.15% year-over-year to $80.3 million; the TTM value through Sep 2025 reached $80.3 million, up 168.15%, while the annual FY2024 figure was $29.8 million, N/A changed from the prior year.
  • Long-Term Investments reached $80.3 million in Q3 2025 per STOK's latest filing, down from $107.3 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $107.3 million in Q2 2025 and bottomed at $23.0 million in Q1 2025.